Sudden winter iloprost withdrawal in scleroderma patients during COVID-19 pandemic.
COVID-19
Iloprost
Nailfold capillaroscopy
Systemic sclerosis
Journal
Microvascular research
ISSN: 1095-9319
Titre abrégé: Microvasc Res
Pays: United States
ID NLM: 0165035
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
02
03
2022
revised:
27
06
2022
accepted:
05
07
2022
pubmed:
15
7
2022
medline:
14
9
2022
entrez:
14
7
2022
Statut:
ppublish
Résumé
Intravenous iloprost is currently recommended in the treatment of Raynaud's phenomenon (RP) refractory to oral therapy and of digital ulcers (DUs) related to systemic sclerosis (SSc). In real-life practice there is a huge heterogeneity about the Iloprost regimens used. A survey was carried out on SSc patients that interrupted Iloprost infusion to compare acral vascular symptoms just before Iloprost withdrawal and just after the missed infusion. Severity, and frequency of RP, new DUs onset or aggravation of those pre-existing were reported. Last available capillaroscopic images were also evaluated. The analysis includes 50 patients. After iloprost withdrawal, 11 patients reported a RP worsening because of enhanced intensity (p = 0.007). Only 8 patients of them also complained of an increased frequency (p = 0.07). None of the patients experienced digital ulcers for the first-time during quarantine. Among the 27 patients with a history of digital ulcers, 9 reported worsening and 7 recurrence of DUs. Overall, 17 patients (34.0 %) complained of a worsening of SSc vascular acral manifestations, namely RP or DUs. Reduced capillary density was associated with RP worsening, in particular, each unit increase of capillary density corresponds to an average 44 % decrease in the odds of RP worsening (OR 0.56, CI 95 % 0.36-0.97, p = 0.037). As for RP worsening, the aggravation of DU was associated with a lower capillary density. Low capillary density can predict a worsening of both RP and DUs in controlled quarantine conditions within a month after iloprost discontinuation in SSc patients.
Identifiants
pubmed: 35835174
pii: S0026-2862(22)00094-2
doi: 10.1016/j.mvr.2022.104404
pmc: PMC9271454
pii:
doi:
Substances chimiques
Iloprost
JED5K35YGL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104404Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest There are no competing interests for any author. All the authors gave substantial contributions to the conception or design of the work, acquisition, analysis or interpretation of data, drafting the work or revising it critically for important intellectual content and final approval of the version published.
Références
J Rheumatol. 2019 Oct;46(10):1326-1334
pubmed: 30824643
Rheumatology (Oxford). 2014 Feb;53(2):376-7
pubmed: 24307291
Acta Dermatovenerol Alp Pannonica Adriat. 2011;20(1):13-21
pubmed: 21879200
Microvasc Res. 2021 Jan;133:104071
pubmed: 32949574
Clin Exp Med. 2019 Aug;19(3):357-366
pubmed: 30989453
G Ital Dermatol Venereol. 2013 Apr;148(2):209-16
pubmed: 23588147
J Scleroderma Relat Disord. 2021 Feb;6(1):109-110
pubmed: 35382250
Rheumatology (Oxford). 2015 Jan;54(1):72-6
pubmed: 25065009
Autoimmun Rev. 2020 Mar;19(3):102458
pubmed: 31927087
Ann Rheum Dis. 2017 Aug;76(8):1327-1339
pubmed: 27941129
J Am Acad Dermatol. 2009 Mar;60(3):426-35
pubmed: 19231640